Petros Pharmaceuticals, Inc. (PTPI): Marketing Mix Analysis [Dec-2025 Updated]

You're digging into Petros Pharmaceuticals, Inc. and trying to map out their strategy, which is smart because this company is actively transforming from a specialty pharma player into a tech-enabled Rx-to-OTC facilitator. Honestly, the core of their current marketing mix isn't just STENDRA®, which has a high list price around $677.70, but their proprietary SaaS platform targeting the emerging $38 billion self-care market. The financial proof of this pivot is clear: they logged a $5.43M Net Income in Q2 2025, a significant swing after that $26.80 million loss in 2024. So, how does a company manage that transition across Product, Place, Promotion, and Price? Read on to see the precise breakdown of the four P's driving this evolving business model.

Petros Pharmaceuticals, Inc. (PTPI) - Marketing Mix: Product

You're looking at the core offering of Petros Pharmaceuticals, Inc. (PTPI) as the company pivots its focus. The product strategy centers on leveraging technology to expand access to medications, moving away from direct commercialization of certain legacy products.

STENDRA® (avanafil), a prescription PDE-5 inhibitor indicated for Erectile Dysfunction (ED), was a key component of the previous business model. However, as of the latest reports, Petros Pharmaceuticals, Inc. has discontinued sales of STENDRA® and is no longer involved in the marketing or selling of associated vacuum erection devices following assignment to a third party.

The primary current product focus is the proprietary technology platform, which includes a SaaS (Software as a Medical Device) solution designed to facilitate the Rx-to-OTC switch for other pharmaceutical companies. This proprietary technology-assisted platform is being developed to help partners meet FDA standards for over-the-counter access. The platform integrates AI and big data solutions. Specific technological enhancements implemented to the AI platform include:

• Addition of Deep Fake detection and mitigation features.
• Improved facial and ID recognition and matching capabilities.
• Enhanced image auto capture feature powered by machine learning technology.

The utility of this technology in consumer comprehension, critical for an OTC switch, was tested. In a pivotal study aligned with FDA guidelines, the technology demonstrated encouraging performance. The results from a 400 patient-consumer study involving 31 objectives showed success against critical thresholds:

• Achieved 4 of 5 among the most critical objectives.
• Achieved 9 of 9 of the next tier critical objectives.
• All 17 important objectives exceeded an 84% LB threshold.

An earlier iteration of this study showed patients interacting with the technology achieved 30 out of 31 objectives to the LB thresholds required for FDA meaningfulness. This positions Petros Pharmaceuticals, Inc. to benefit from the recently adopted "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" ("ACNU") rules by the United States Food and Drug Administration (the "FDA").

Regarding H100, a patented topical formulation candidate for acute Peyronie's disease, specific development status or clinical trial data is not detailed in the latest public announcements, though the company remains focused on expanding access within the self-care sector.

The strategic product development is aimed squarely at the emerging self-care market, which Petros Pharmaceuticals, Inc. aims to innovate within. The latest available market sizing data frames the opportunity:

The company completed a public offering in February 2025, raising approximately $9.6 million to support working capital and general corporate purposes.

Petros Pharmaceuticals, Inc. (PTPI) - Marketing Mix: Place

The Place strategy for Petros Pharmaceuticals, Inc. reflects a significant pivot in late 2025, moving away from direct product commercialization toward enabling distribution via a technology platform.

Traditional Distribution Channels (Historical/Transitioning for STENDRA®)

• STENDRA® sales and marketing activities have been discontinued as of the March 31, 2025, 10-K filing.
• Prior coverage for STENDRA® reached approximately 75% of commercially insured lives.
• Prior co-pay for STENDRA® was as low as $0.
• Historical distribution relied on sales representatives targeting high-volume physician prescribers.
• Targeting of managed care organizations was used to improve placement on approved drug lists.

Direct-to-Consumer Channel via Telehealth Partnerships

The partnership with Lemonaid Health established a direct channel for prescription STENDRA® distribution across the United States.

• Lemonaid Health has treated over 200,000 male patients with erectile dysfunction to date.
• The platform provides access to medication delivery from a 50 state licensed pharmacy.

Technology Platform Integration and Licensing Model

The primary current 'Place' strategy involves the distribution and potential licensing of the proprietary Rx-to-OTC SaaS/SaMD platform to other pharmaceutical companies.

The self-care market, which the platform is designed to serve, is currently estimated to be valued over $38 billion.

This market segment has an expected compounded annual growth rate of 5.6% over the next 10 years.

The platform development is anchored in compliance with FDA rules, such as the Nonprescription Drug Product with an Additional Condition for Nonprescription Use rule (ACNU Rule), and frameworks like the Trusted Exchange Framework and Common Agreement (TEFCA) for health information sharing.

The company raised approximately $9.6 million in a February 2025 public offering to support working capital and general corporate purposes, funding technology development.

As of May 21, 2025, the company reported having over $10 million in cash.

The platform's technology includes:

• Deep Fake detection and mitigation features.
• Improved facial and ID recognition and matching capabilities.
• Enhanced image auto capture feature powered by machine learning technology.

The company believes its technology could provide significant opportunities for future pharma partnerships.

The company's securities began trading on the OTC Markets under the ticker 'PTPI' on May 22, 2025.

Petros Pharmaceuticals, Inc. (PTPI) - Marketing Mix: Promotion

Promotion for Petros Pharmaceuticals, Inc. centers on establishing its proprietary technology platform as the essential bridge for pharmaceutical partners navigating regulatory pathways to expand consumer access to medication.

Public relations focused on aligning the proprietary technology with FDA ACNU guidelines

Public relations efforts heavily emphasize the alignment of the proprietary technology with the United States Food and Drug Administration (FDA) final rule, "Nonprescription Drug Product with an Additional Condition for Nonprescription Use" ("ACNU"). The final rule was published on December 26, 2024, with an effective date delayed to May 27, 2025. Petros Pharmaceuticals, Inc. has publicly highlighted its position at the forefront of these emerging requirements, noting that its development was guided by earlier iterations of the rule and incorporated periodic feedback from the FDA. This strategic communication positions the company as a leader in the emerging self-care market, which is currently estimated to be valued over $38 billion.

Key public relations milestones communicated include:

• Alignment with the April 15, 2025 President Trump Executive Order on Rx-to-OTC reforms.
• Development of a Software as a Medical Device (SaMD) concept designed for the self-care market.
• A recent pivotal study involving 400 patient-consumers demonstrating technology-facilitated understanding of critical objectives.

Highlighting the platform's AI and Big Data capabilities to drive industry collaboration

The promotional narrative stresses the technological sophistication underpinning the ACNU pathway navigation. Petros Pharmaceuticals, Inc. has announced multiple enhancements to its developing Artificial Intelligence (AI) platform, which is a key component of its Software as a Service (SaaS) and SaMD solution. This technology is being developed in collaboration with a renowned Big Data provider. The focus is on driving industry collaboration by offering a commercially viable, licensable single framework.

Specific AI enhancements promoted to potential partners include:

• Addition of Deep Fake detection and mitigation features.
• Improved facial and ID recognition and matching capabilities.
• Enhanced image auto capture feature powered by machine learning technology.

The company is striving to become a leading innovator in this sector, which is projected to grow at a compounded annual growth rate of 5.6% over the next decade.

Sales promotions and personal selling directed at pharmacies and medical facilities (push strategy)

While specific sales promotion expenditure or personal selling metrics are not publicly detailed, the push strategy is inferred through the platform's intended function as a licensable SaaS and SaMD solution directed at pharmaceutical manufacturers. The platform is designed to integrate with retail pharmacies, suggesting a future channel push. The company's Q3 2025 Net Sales were reported at $0.71 million, down from $1.39 million the prior year, providing a financial context for current commercial activities. The current ratio of 0.4 indicates a tight liquidity position that influences the scale of direct promotional investment.

Marketing the potential for expanded consumer access to medication via OTC switch

Marketing centers on the potential societal and commercial benefit of expanding consumer access. The company believes its technology could facilitate Rx-to-OTC switches for several indications. The core message is that the technology ensures consumers can make an appropriate informed decision based only upon the information provided via the platform, which is necessary for FDA approval.

The potential scope of the OTC switch opportunity is quantified by:

The company is focused on leveraging this platform to drive expanded access to key nonprescription pharmaceuticals through a retail or online interface with clinically established algorithmic logic to qualify consumer-patients for ACNU Products. This strategy is intended to help lower drug prices.

Petros Pharmaceuticals, Inc. (PTPI) - Marketing Mix: Price

Price involves the monetary value customers exchange for Petros Pharmaceuticals, Inc. (PTPI) offerings, which now centers on a strategic shift away from legacy drug sales toward a technology licensing model.

For the legacy product, STENDRA®, the pricing structure involved a high list price, which was heavily offset by patient assistance programs. The list price was reported at approximately $677.70.

To make the product accessible, significant price concessions were made at the point of sale. Coupon programs, such as those facilitated by GoodRx, could reduce the out-of-pocket cost to as low as $160.91.

Further enhancing patient access, co-pay assistance programs were structured to result in a co-pay as low as $0 for roughly 75% of commercially insured lives.

The current pricing strategy is pivoting to support the new business focus. Petros Pharmaceuticals, Inc. is establishing a new B2B revenue model centered on licensing its proprietary SaaS platform, which is designed to facilitate the Rx-to-OTC switch for other pharmaceutical companies. This represents a shift from direct drug sales revenue to technology service revenue.

The company's recent financial performance reflects this transition and the discontinuation of legacy revenue streams. You can see the key financial metrics below:

The pricing and accessibility strategy for the previous drug product was characterized by high list prices counterbalanced by aggressive patient-facing discounts. The new pricing strategy for the SaaS platform will be based on licensing fees and service agreements, targeting pharmaceutical partners rather than individual consumers.

Key elements related to the pricing environment and strategic shift include:

• High list price for STENDRA®: $677.70
• Coupon-reduced price floor for STENDRA®: $160.91
• Co-pay reduction target for STENDRA®: $0 for approximately 75% of insured lives
• Reported Q2 2025 Net Income: $5.43M
• Reported 2024 Net Loss: -$26.80 million

The company's focus is now on monetizing its technology through B2B licensing, which implies a different pricing structure involving enterprise-level contracts for the licensable SaaS platform.